Kezar Life Sciences KZR

$ 7.53 0.53%

Quarterly report 2024-Q3
added 11-12-2024

Kezar Life Sciences Balance Sheet 2011-2024 | KZR

Annual Balance Sheet Kezar Life Sciences

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-22.4 M	-28.1 M	-52.1 M	-15.8 M	-8.59 M	-24.2 M	-51 M	-9.75 M	-	-	-	-	-
Long Term Debt	10.1 M	9.83 M	9.62 M	4.42 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	3.01 M	2.56 M	1.2 M	1.04 M	900 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	5.46 M	2.55 M	78.4 M	28.2 M	-	-	-	-	-
Total Current Liabilities	17.7 M	11 M	8.21 M	6.44 M	6 M	3.34 M	-	-	-	-	-	-	-
Total Liabilities	33.7 M	29.7 M	21.1 M	10.9 M	11.5 M	5.88 M	79.9 M	28.9 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-351 M	-249 M	-181 M	-126 M	-84.3 M	-49.2 M	-26 M	-17.5 M	-	-	-	-	-
Total Assets	221 M	300 M	218 M	152 M	89.5 M	115 M	54.2 M	11.4 M	-	-	-	-	-
Cash and Cash Equivalents	35.5 M	40.5 M	62.9 M	21.2 M	15 M	24.2 M	51 M	9.76 M	-	-	-	-	-
Book Value	188 M	270 M	197 M	141 M	78 M	109 M	-25.7 M	-17.4 M	-	-	-	-	-
Total Shareholders Equity	188 M	270 M	197 M	141 M	78 M	109 M	-25.7 M	-17.4 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Kezar Life Sciences

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	6.35 M	7.59 M	8.83 M	10.1 M	10 M	9.95 M	9.89 M	9.83 M	9.78 M	9.73 M	9.68 M	9.62 M	3.54 M	3.84 M	4.14 M	4.42 M	4.42 M	4.42 M	4.42 M	5.46 M	5.46 M	5.46 M	5.46 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	30 M	29.2 M	30 M	33.7 M	33.3 M	31.1 M	31.7 M	29.7 M	21.6 M	20.1 M	19.6 M	21.1 M	11.4 M	9.79 M	11.7 M	10.9 M	10.9 M	10.9 M	10.9 M	11.5 M	11.5 M	11.5 M	11.5 M	5.88 M	5.88 M	5.88 M	5.88 M	1.98 M	1.98 M	1.98 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-414 M	-394 M	-372 M	-351 M	-319 M	-295 M	-271 M	-249 M	-231 M	-213 M	-197 M	-181 M	-166 M	-152 M	-139 M	-126 M	-126 M	-126 M	-126 M	-84.3 M	-84.3 M	-84.3 M	-84.3 M	-49.2 M	-49.2 M	-49.2 M	-49.2 M	-26 M	-26 M	-26 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	164 M	180 M	199 M	221 M	249 M	263 M	284 M	300 M	305 M	318 M	252 M	218 M	131 M	140 M	152 M	152 M	152 M	152 M	152 M	89.5 M	89.5 M	89.5 M	89.5 M	115 M	115 M	115 M	115 M	54.2 M	54.2 M	54.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	34.9 M	28.3 M	33 M	35.5 M	26.5 M	28.1 M	36.1 M	40.5 M	64.5 M	105 M	38.9 M	62.9 M	57.1 M	26.4 M	22.9 M	21.2 M	21.2 M	21.2 M	21.2 M	15 M	15 M	15 M	15 M	24.2 M	24.2 M	24.2 M	24.2 M	51 M	51 M	51 M	-	9.75 M	-	-	-	19.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	134 M	151 M	169 M	188 M	216 M	232 M	252 M	270 M	283 M	297 M	232 M	197 M	119 M	130 M	141 M	141 M	141 M	141 M	141 M	78 M	78 M	78 M	78 M	109 M	109 M	109 M	109 M	52.2 M	52.2 M	52.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	134 M	151 M	169 M	188 M	216 M	232 M	252 M	270 M	283 M	297 M	232 M	197 M	119 M	130 M	141 M	141 M	141 M	141 M	141 M	78 M	78 M	78 M	78 M	109 M	109 M	109 M	109 M	-25.7 M	-25.7 M	-25.7 M	-	-17.4 M	-	-	-	-8.42 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency